Rx Peps Direct data shows 48% BPC-157 use among patients
The announcement presents Rx Peps Direct order data from 4,099 paid orders placed by 2,209 patients between May 13 and November 6, 2026, indicating that 60 percent of patients ordered at least one of the six peptides named in the HHS compounding policy published on October 30. Those peptides are BPC-157, TB-500, KPV, MOTS-c, Semax and Epitalon. BPC-157 led usage with 48 percent of patients, or 1,055 individuals, ordering a product containing it. The six peptides appeared together in 52 percent of monthly orders from August through October. Every order received review by a licensed provider at the online clinic. These results describe only Rx Peps Direct patients.
The announcement details patient shares for each peptide drawn from the full set of 2,209 patients. BPC-157 reached 48 percent or 1,055 patients. TB-500 followed at 39 percent or 869 patients. KPV stood at 27 percent or 598 patients. MOTS-c reached 17 percent or 385 patients. Semax accounted for 8 percent or 173 patients. Epitalon reached 5 percent or 100 patients. Men ordered BPC-157 at a 55 percent rate versus 38 percent for women and ordered TB-500 at 45 percent versus 32 percent for women. KPV showed equal 27 percent shares for both genders. Epitalon was the sole peptide ordered by a higher share of women at 6 percent versus 4 percent for men.
The announcement reports a median patient age of 45 across the six peptides with 37 percent of users aged 50 or older. Age-group shares ordering at least one of the six peptides were 53 percent for patients in their 20s, 59 percent for those in their 30s, 60 percent for those in their 40s, 63 percent for those in their 50s, 61 percent for those in their 60s, and 54 percent for those 70 and older. Men accounted for 55 percent of BPC-157 orders and 45 percent of TB-500 orders while women showed lower corresponding shares. The announcement notes that more than half of patients in every age group from the 20s onward ordered one of the six peptides.
The announcement covers reorder rates among patients whose first order occurred at least 45 days earlier along with GLP-1 co-ordering and state concentrations. Reorder rates reached 53 percent for BPC-157 among 476 qualifying patients, 54 percent for TB-500 among 381 patients, 53 percent for KPV among 267 patients, 39 percent for MOTS-c among 119 patients, 17 percent for Semax among 60 patients, and 30 percent for Epitalon among 33 patients. Twenty-one percent of patients using any of the six peptides also ordered a GLP-1 medication such as tirzepatide or semaglutide, rising to 33 percent among Epitalon users. Texas recorded the highest concentration with 354 patients using the six peptides followed by Florida with 232 patients.
The announcement presents monthly order trends showing the six peptides maintained a consistent share of total orders from August through October. In August the peptides appeared in 331 of 639 orders or 52 percent. In September they appeared in 614 of 1,176 orders or 52 percent. In October they appeared in 794 of 1,522 orders or 52 percent. Earlier months showed different volumes with June at 36 of 64 orders or 56 percent and July at 138 of 298 orders or 46 percent. The announcement states these shares held steady during the later period covered by the data.
The announcement explains the data collection method and states explicit limitations. Every paid order placed in the period was counted regardless of whether a provider approved it, was still reviewing it, or declined it. Test accounts and unpaid checkouts were excluded. Patients were matched by email address. Sex reflects the value entered at intake with 1,278 men and 930 women recorded. Age reflects the value at the latest order. A patient counts toward a peptide if any ordered product listed it as an ingredient. The announcement states these figures describe only Rx Peps Direct patients and do not support national inference about peptide use.
The announcement notes smaller sample sizes for Semax and Epitalon when reporting reorder rates and other metrics. The Semax reorder group contained 60 patients and the Epitalon group contained 33 patients. It states that these smaller groups limit the precision of associated percentages such as the 17 percent reorder rate for Semax and the 30 percent reorder rate for Epitalon. No other age or gender anomalies beyond the reported shares are identified in the announcement for these two peptides.
